Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CHPG is a selective agonist of mGluR5. In BV2 microglial cells, it attenuates SO2-induced oxidative stress and inflammation through the TSG-6/NF-κB pathway.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 877.00 | |
50 mg | 6-8 weeks | $ 1,140.00 | |
100 mg | 6-8 weeks | $ 1,730.00 |
Description | CHPG is a selective agonist of mGluR5. In BV2 microglial cells, it attenuates SO2-induced oxidative stress and inflammation through the TSG-6/NF-κB pathway. |
In vitro | CHPG (0.5?mM; 30?mins ) protects BV2 cells against SO2-induced apoptosis. CHPG (10-500?μM; 24?hours) significantly increases the cell viability and decreases the LDH release after SO2 derivatives treatment. CHPG (0.5?mM; 30?mins) treatment alone increases the expression of TSG-6 in both mRNA and protein levels [1]. |
In vivo | CHPG (injection; 250 nM; for 7 days) reduces significantly cerebral lesion volume [2]. |
Molecular Weight | 201.61 |
Formula | C8H8ClNO3 |
CAS No. | 170846-74-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CHPG 170846-74-9 Others inhibitor inhibit